Oncoinvent ASA (0RU5)
LSE
Real-time Data
07:00 AM
Day's Range
70.2052 wk Range
0.4400Overview - 0RU5 - Oncoinvent ASA
Key Statistics
Valuation
Enterprise Value
140.33M
P/E (Trailing)
‪292.49‬
PEG Ratio
‪0.54‬
Price / Sales (TTM)
‪6.40‬
Price / Book
‪2.14‬
EV / EBITDA
‪-0.93‬
Profitability
Gross Margin
‪14.83%‬
Profit Margin
‪34.25%‬
Operating Margin
‪-659.95%‬
Return on Assets
‪-52.63%‬
Return on Equity
‪-121.78%‬
Ownership
Shares Outstanding
54.71M
Float
2.99M
Held by Insiders
‪23.07%‬
Held by Institutions
‪38.69%‬
Price stats
50-Day Avg
‪0.2624‬
200-Day Avg
‪0.5130‬
Market Cap - 0RU5 - Oncoinvent ASA
Peers - 0RU5 - Oncoinvent ASA
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0RU5LSEOncoinvent ASA3.84BMarket Cap+98.28%52-week change292.50P/E (Trailing)‪34.25%‬Profit Margin
- 0MGBLSEGenmab A/S168.24BMarket Cap+25.25%52-week change30.65P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.31BMarket Cap+29.11%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.90.49BMarket Cap+30.71%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.66.31BMarket Cap+81.03%52-week change55.34P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE51.17BMarket Cap+30.71%52-week change41.26P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.92BMarket Cap+9.88%52-week change127.93P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0RU5 - Oncoinvent ASA
About
Oncoinvent ASA is a Norwegian clinical-stage biotechnology company focused on developing radiopharmaceutical therapies for cancer treatment. Its lead product candidate, Radspherin, is an investigational alpha-radiation therapy using calcium carbonate microparticles loaded with the radionuclide radium-224. Designed for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
